Physiomics PLC Conference presentation
12 Novembro 2021 - 9:00AM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
12 November 2021
12 November 2021
Physiomics plc
("Physiomics") or ("the Company")
Conference presentation
Physiomics and Bicycle Therapeutics to present on preclinical
modelling of an immune therapy at SITC 2021 Annual Meeting
Physiomics plc (AIM: PYC), a provider of technology-based
solutions to predict the effects of cancer treatment regimens for
the biopharma industry, is pleased to announce that it is
presenting a poster at the Society for Immunotherapy of Cancer's
(SITC) 36(th) Annual Meeting taking place at the Walter E.
Washington Convention Center, Washington, USA from 10-14 November
2021.
The Company and its client Bicycle Therapeutics will today be
presenting an original poster (abstract #826) in an ePoster format.
The poster is titled "Establishing the preclinical/translational
PK/PD relationship for BT7480, a Nectin-4/CD137 Bicycle
tumor-targeted immune cell agonist(TM) (Bicycle TICA(TM))".
The Company's modelling determined that the level of tumour
infiltrating CD8+ T-cells fully captures the treatment effect of
BT7480 on tumour growth in an in vivo preclinical model. A PK/PD
modelling framework was developed that predicts preclinical
biomarker level and tumour growth inhibition in response to changes
in the BT7480 dose and dosing schedule.
More information about the conference can be found using the
following link: https://www.sitcancer.org/2021/home .
The poster is now available on the Physiomics website at this
link: https://www.physiomics.co.uk/resources/ .
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 80 projects, involving over 40 targets and
70 drugs, and has worked with clients such as Merck KGaA, Astellas,
Merck & Co and Bicycle Therapeutics.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAZZMGMGRDGMZM
(END) Dow Jones Newswires
November 12, 2021 07:00 ET (12:00 GMT)
Physiomics (LSE:PYC)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Physiomics (LSE:PYC)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024